## Jeanine E Roeters Van Lennep

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/895346/publications.pdf

Version: 2024-02-01

89 papers

2,884 citations

28 h-index 51 g-index

95 all docs 95
docs citations

95 times ranked 3907 citing authors

#	Article	IF	CITATIONS
1	Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation. Inflammatory Bowel Diseases, 2023, 29, 531-538.	0.9	8
2	Prevalence of microvascular angina among patients with stable symptoms in the absence of obstructive coronary artery disease: a systematic review. Cardiovascular Research, 2022, 118, 763-771.	1.8	16
3	Variability in lipid measurements can have major impact on treatment during secondary prevention. European Journal of Preventive Cardiology, 2022, 28, e4-e5.	0.8	O
4	Moving from intention to behaviour: a randomised controlled trial protocol for an app-based physical activity intervention (i2be). BMJ Open, 2022, 12, e053711.	0.8	2
5	Quality of life and coping in Dutch homozygous familial hypercholesterolemia patients: A qualitative study. Atherosclerosis, 2022, 348, 75-81.	0.4	3
6	Spotlight on Cardiovascular Risk Assessment in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2022, 67, 4326-4329.	1,1	1
7	Association between maternal thyroid function and risk of gestational hypertension and pre-eclampsia: a systematic review and individual-participant data meta-analysis. Lancet Diabetes and Endocrinology,the, 2022, 10, 243-252.	5.5	49
8	Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. European Journal of Preventive Cardiology, 2022, 29, 832-841.	0.8	23
9	Maternal lipid profile in pregnancy and embryonic size: a population-based prospective cohort study. BMC Pregnancy and Childbirth, 2022, 22, 333.	0.9	5
10	Sex Differences in Reported Adverse Drug Reactions to Angiotensin-Converting Enzyme Inhibitors. JAMA Network Open, 2022, 5, e228224.	2.8	10
11	Is Liver Transplant Curative in Homozygous Familial Hypercholesterolemia? A Review of Nine Global Cases. Advances in Therapy, 2022, 39, 3042-3057.	1.3	14
12	Perceived determinants of physical activity among women with prior severe preeclampsia: a qualitative assessment. BMC Women's Health, 2022, 22, 133.	0.8	O
13	Comprehensive (apo)lipoprotein profiling in patients with genetic hypertriglyceridemia using LC-MS and NMR spectroscopy. Journal of Clinical Lipidology, 2022, 16, 472-482.	0.6	10
14	Sex-specific anthropometric and blood pressure trajectories and risk of incident atrial fibrillation: the Rotterdam Study. European Journal of Preventive Cardiology, 2022, 29, 1744-1755.	0.8	3
15	Longitudinal Anthropometric Measures and Risk of New-Onset Atrial Fibrillation Among Community-Dwelling Men and Women. Mayo Clinic Proceedings, 2022, 97, 1501-1511.	1.4	2
16	Prevalence of ideal cardiovascular health and its correlates in patients with inflammatory bowel disease, psoriasis and spondyloarthropathy. European Journal of Preventive Cardiology, 2022, 29, e314-e318.	0.8	2
17	Screening for coronary artery calcium in a high-risk population: the ROBINSCA trial. European Journal of Preventive Cardiology, 2021, 28, 1155-1159.	0.8	6
18	Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinibâ€"Implications for Cardiovascular Risk and Patient Management. Inflammatory Bowel Diseases, 2021, 27, e25-e25.	0.9	1

#	Article	IF	CITATIONS
19	Subjects with familial hypercholesterolemia have lower aortic valve area and higher levels of inflammatory biomarkers. Journal of Clinical Lipidology, 2021, 15, 134-141.	0.6	6
20	Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study). JMIR Research Protocols, 2021, 10, e24414.	0.5	9
21	How significant is the antifibrinolytic effect of lipoprotein(a) for blood clot lysis?. Thrombosis Research, 2021, 198, 210-212.	0.8	4
22	Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis, 2021, 319, 108-117.	0.4	18
23	Angiogenic markers during preeclampsia: Are they associated with hypertension 1Âyear postpartum?. Pregnancy Hypertension, 2021, 23, 116-122.	0.6	6
24	Long term follow-up of children with familial hypercholesterolemia and relatively normal LDL-cholesterol at diagnosis. Journal of Clinical Lipidology, 2021, 15, 375-378.	0.6	2
25	Novel associations between parental and newborn cord blood metabolic profiles in the Norwegian Mother, Father and Child Cohort Study. BMC Medicine, 2021, 19, 91.	2.3	8
26	Sex Differences in Lipid Profile across the Life Span in Patients with Type 2 Diabetes: A Primary Care-Based Study. Journal of Clinical Medicine, 2021, 10, 1775.	1.0	4
27	Cholesterol at ages 6, 12 and 24 months: Tracking and associations with diet and maternal cholesterol in the Infant Cholesterol Study. Atherosclerosis, 2021, 326, 11-16.	0.4	5
28	Aging, Cardiovascular Risk, and SHBG Levels in Men and Women From the General Population. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2890-2900.	1.8	16
29	Lipoprotein(a) levels and atherosclerotic plaque characteristics in the carotid artery: The Plaque at RISK (PARISK) study. Atherosclerosis, 2021, 329, 22-29.	0.4	21
30	Systematic review with metaâ€analysis: effect of inflammatory bowel disease therapy on lipid levels. Alimentary Pharmacology and Therapeutics, 2021, 54, 999-1012.	1.9	7
31	Advancing Sex and Gender Considerations in Peri-operative Cardiovascular Risk Assessment. Canadian Journal of Cardiology, 2021, , .	0.8	1
32	Loss of statin treatment years during pregnancy and breastfeeding periods in women with familial hypercholesterolemia. Atherosclerosis, 2021, 335, 8-15.	0.4	23
33	Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110321.	1.4	12
34	The cardiovascular risk profile of middleâ€aged women with polycystic ovary syndrome. Clinical Endocrinology, 2020, 92, 150-158.	1.2	36
35	Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis, 2020, 292, 178-187.	0.4	41
36	The development and first results of a health-related outcomes set in familial hypercholesterolemia (FH) patients: Knowledge is health. Atherosclerosis, 2020, 293, 11-17.	0.4	9

#	Article	IF	CITATIONS
37	Cardiovascular health and vascular age after severe preeclampsia: A cohort study. Atherosclerosis, 2020, 292, 136-142.	0.4	4
38	Maternal lipid profile in early pregnancy is associated with foetal growth and the risk of a child born large-for-gestational age: a population-based prospective cohort study. BMC Medicine, 2020, 18, 276.	2.3	39
39	Early Onset of Coronary Artery Calcification in Women With Previous Preeclampsia. Circulation: Cardiovascular Imaging, 2020, 13, e010340.	1.3	32
40	Catamenial chest pain and spontaneous coronary artery dissection: A case report. Case Reports in Women's Health, 2020, 28, e00256.	0.2	4
41	Gestational lipid profile as an early marker of metabolic syndrome in later life: a population-based prospective cohort study. BMC Medicine, 2020, 18, 394.	2.3	12
42	The cardiovascular risk profile of middle age women previously diagnosed with premature ovarian insufficiency: A case-control study. PLoS ONE, 2020, 15, e0229576.	1.1	21
43	Screening for cardiovascular disease risk using traditional risk factor assessment or coronary artery calcium scoring: the ROBINSCA trial. European Heart Journal Cardiovascular Imaging, 2020, 21, 1216-1224.	0.5	43
44	Adverse Events Associated With <scp>PCSK</scp> 9 Inhibitors: A Realâ€World Experience. Clinical Pharmacology and Therapeutics, 2019, 105, 496-504.	2.3	51
45	Mast Cells in Cardiovascular Disease: From Bench to Bedside. International Journal of Molecular Sciences, 2019, 20, 3395.	1.8	34
46	Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype. Atherosclerosis, 2019, 289, 201-205.	0.4	41
47	Lipoprotein(a) concentration is associated with plasma arachidonic acid in subjects with familial hypercholesterolaemia. British Journal of Nutrition, 2019, 122, 790-799.	1.2	4
48	Variation in Coronary Atherosclerosis Severity Related to a Distinct LDL (Low-Density Lipoprotein) Profile. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2338-2352.	1.1	19
49	Future risk of cardiovascular disease risk factors and events in women after a hypertensive disorder of pregnancy. Heart, 2019, 105, 1273-1278.	1.2	139
50	Treatment with Statins Does Not Revert Trained Immunity in Patients with Familial Hypercholesterolemia. Cell Metabolism, 2019, 30, 1-2.	7.2	130
51	Is maternal lipid profile in early pregnancy associated with pregnancy complications and blood pressure in pregnancy and long term postpartum?. American Journal of Obstetrics and Gynecology, 2019, 221, 150.e1-150.e13.	0.7	63
52	Reply to: "The "cholesterol paradox―in patients with mastocytosis― Atherosclerosis, 2019, 284, 262-263.	0.4	1
53	Placental Growth Factor as an Indicator of Maternal Cardiovascular Risk After Pregnancy. Circulation, 2019, 139, 1698-1709.	1.6	38
54	Prevalence of Subclinical Coronary Artery Disease Assessed by Coronary Computed Tomography Angiography in 45- to 55-Year-Old Women With a History of Preeclampsia. Circulation, 2018, 137, 877-879.	1.6	51

#	Article	IF	Citations
55	Sex differences in cholesterol levels from birth to 19Âyears of age may lead to increased cholesterol burden in females with FH. Journal of Clinical Lipidology, 2018, 12, 748-755.e2.	0.6	19
56	Blood Pressure Profile 1 Year After Severe Preeclampsia. Hypertension, 2018, 71, 491-498.	1.3	78
57	Maternal lipid profile 6 years after a gestational hypertensive disorder. Journal of Clinical Lipidology, 2018, 12, 428-436.e4.	0.6	11
58	Why women are not small men. Maturitas, 2018, 107, A3-A4.	1.0	3
59	Systemic mastocytosis associates with cardiovascular events despite lower plasma lipid levels. Atherosclerosis, 2018, 268, 152-156.	0.4	20
60	Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. Data in Brief, 2018, 21, 1334-1336.	0.5	4
61	No effect of PCSK9 inhibitors on D-dimer and fibrinogen levels in patients with familial hypercholesterolemia. Biomedicine and Pharmacotherapy, 2018, 108, 1412-1414.	2.5	11
62	The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study. Journal of Clinical Lipidology, 2018, 12, 898-907.e2.	0.6	44
63	Hypertensive disorders of pregnancy and subsequent maternal cardiovascular health. European Journal of Epidemiology, 2018, 33, 763-771.	2.5	33
64	Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: AÂmodel that explores the efficacy of conventional and novel lipid-lowering therapy. Journal of Clinical Lipidology, 2018, 12, 972-980.e1.	0.6	16
65	Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score― Atherosclerosis, 2018, 275, 265-272.	0.4	131
66	Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 507-514.	0.6	19
67	Low-density lipoprotein receptor–negative compound heterozygous familial hypercholesterolemia: Two lifetime journeys of lipid-lowering therapy. Journal of Clinical Lipidology, 2017, 11, 301-305.	0.6	3
68	Effect of diet-induced weight loss on lipoprotein(a) levels in obese individuals with and without type 2 diabetes. Diabetologia, 2017, 60, 989-997.	2.9	30
69	Toward an international consensus—Integrating lipoprotein apheresis and new lipid-lowering drugs. Journal of Clinical Lipidology, 2017, 11, 858-871.e3.	0.6	105
70	Cascade screening for familial hypercholesterolemia: Practical consequences. Atherosclerosis Supplements, 2017, 30, 77-85.	1.2	61
71	Carotid artery plaques and intima medial thickness in familial hypercholesteraemic patients on long-term statin therapy: A case control study. Atherosclerosis, 2017, 256, 62-66.	0.4	23
72	Monogenetic disorders of the cholesterol metabolism and premature cardiovascular disease. European Journal of Pharmacology, 2017, 816, 146-153.	1.7	8

#	Article	IF	CITATIONS
73	Soluble LR11 associates with aortic root calcification in asymptomatic treated male patients with familial hypercholesterolemia. Atherosclerosis, 2017, 265, 299-304.	0.4	7
74	Cardiovascular Riskprofile - IMaging and gender-specific disOrders (CREw-IMAGO): rationale and design of a multicenter cohort study. BMC Women's Health, 2017, 17, 60.	0.8	16
75	Gestational hypertensive disorders and retinal microvasculature: the Generation R Study. BMC Medicine, 2017, 15, 153.	2.3	14
76	Cardiovascular risk management after reproductive and pregnancy-related disorders: A Dutch multidisciplinary evidence-based guideline. European Journal of Preventive Cardiology, 2016, 23, 1863-1879.	0.8	121
77	Knowledge equals health; why all healthcare professionals should know about familial hypercholesterolemia. Atherosclerosis, 2016, 252, 188-189.	0.4	3
78	Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported disease. Journal of Clinical Lipidology, 2016, 10, 1462-1469.	0.6	25
79	Dose wisely! How lipid-lowering undertreatment can lead to overtreatment. Atherosclerosis, 2016, 255, 126-127.	0.4	3
80	Cardiovascular disease risk in women with premature ovarian insufficiency: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 2016, 23, 178-186.	0.8	178
81	Increased Aortic Valve Calcification inÂFamilial Hypercholesterolemia. Journal of the American College of Cardiology, 2015, 66, 2687-2695.	1.2	54
82	Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia. Atherosclerosis, 2015, 242, 226-229.	0.4	28
83	Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide. Journal of Clinical Lipidology, 2015, 9, 607-617.	0.6	40
84	Bone health and coronary artery calcification: The Rotterdam Study. Atherosclerosis, 2015, 241, 278-283.	0.4	37
85	Health in middle-aged and elderly women: A conceptual framework for healthy menopause. Maturitas, 2015, 81, 93-98.	1.0	60
86	Health Status and Psychological Distress in Patients with Non-compaction Cardiomyopathy: The Role of Burden Related to Symptoms and Genetic Vulnerability. International Journal of Behavioral Medicine, 2015, 22, 717-725.	0.8	7
87	Maternal inheritance does not predict cholesterol levels in children with familial hypercholesterolemia. Atherosclerosis, 2015, 243, 155-160.	0.4	28
88	Refinement of Variant Selection for the LDL Cholesterol Genetic Risk Score in the Diagnosis of the Polygenic Form of Clinical Familial Hypercholesterolemia and Replication in Samples from 6 Countries. Clinical Chemistry, 2015, 61, 231-238.	1.5	166
89	Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome. European Heart Journal, 2015, 36, 560-565.	1.0	366